Trial Profile

An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK [mitogen-activated protein kinase] Inhibitor GSK1120212 in Subjects With Solid Tumors or Lymphoma.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 03 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
29 Sep 2011 New source identified and integrated (M.D. Anderson Cancer Center record, 2009-0660).
10 Dec 2010 Planned end date changed from 1 Sep 2009 to 1 May 2011 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com